Literature DB >> 26452

Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment.

F Davidson, R F Mould.   

Abstract

A study of clotrimazole for the treatment of recurrent genital candidosis unexpectedly showed that symptoms and infection can be dissociated. The aim of the study was to see if intermittent antifungal treatment would reduce symptoms in women constantly distressed by recurrent genital candidosis. Forty women seriously affected by the condition were initially given oral and local antifungal treatment. When the patients were symptom-free and the vagina was free of yeasts, they were entered into a double-blind clinical trial and were treated prophylactically for four months with either intermittent clotrimazole pessaries and cream or a placebo. The prophylactic treatment kept symptoms below a critical level but did not affect the return of the yeasts to the vagina. This dissociation between symptoms and vaginal yeasts was unexpected. Rectal yeast carriage was unaffected by prophylactic vaginal treatment. Male contacts and patients both showed a high incidence of non-specific genital infection. This association has seldom been reported. A few patients cultured yeasts from their homes but this environment was not considered a major source of reinfection. The vaginal pH did not appear to be altered by the presence of yeasts. The results of the study suggested that symptoms in women with recurrent genital candidosis were not caused by yeasts alone, and possibly the reason for recurrences might lie not in constant reinfection by yeasts, but in failure to recognise and remove a primary underlying factor, perhaps infection with other sexually transmitted agents. The question of a synergistic action between yeasts and other organisms is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 26452      PMCID: PMC1045485          DOI: 10.1136/sti.54.3.176

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  16 in total

1.  THE VAGINAL ECOLOGY AND ITS RELATIONSHIP TO SYMPTOMS IN VAGINITIS.

Authors:  E B MENDEL; S HABERMAN
Journal:  South Med J       Date:  1965-03       Impact factor: 0.954

2.  Vaginal candidiasis and the role of the digestive tract as a source of infection.

Authors:  A L Hilton; D W Warnock
Journal:  Br J Obstet Gynaecol       Date:  1975-11

3.  Genital yeasts in female patients attending a VD clinic.

Authors:  F E Willmott
Journal:  Br J Vener Dis       Date:  1975-04

4.  The biology of experimental human cutaneous moniliasis (Candida albicans).

Authors:  H I MAIBACH; A M KLIGMAN
Journal:  Arch Dermatol       Date:  1962-02

5.  Incidence and distribution of yeast species and of Trichomonas vaginalis in the vagina of pregnant women.

Authors:  R Hurley; B G Leask; J A Faktor; C I De Fonseka
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-03

6.  Criteria for diagnosis of candida vulvovaginitis in pregnant women.

Authors:  C J Carroll; R Hurley; V C Stanley
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-03

Review 7.  Chronic mucocutaneous candidiasis: model-building in cellular immunity.

Authors:  C H Kirkpatrick; R R Rich; J E Bennett
Journal:  Ann Intern Med       Date:  1971-06       Impact factor: 25.391

8.  Polyester sponge swabs to facilitate examination for genital infection in women.

Authors:  J K Oates; S Selwyn; M R Breach
Journal:  Br J Vener Dis       Date:  1971-08

9.  Yeasts and circumcision in the male.

Authors:  F Davidson
Journal:  Br J Vener Dis       Date:  1977-04

10.  [Diagnosis, pathogenicity and therapy of Candida (author's transl)].

Authors:  V P Mursic
Journal:  MMW Munch Med Wochenschr       Date:  1975-05-23
View more
  21 in total

1.  What to do with the patient with recurrent vulvovaginal candidiasis.

Authors:  J S Bingham
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Management of recurrent vulvovaginal candidiasis: unresolved issues.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

Review 3.  Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis.

Authors:  I W Fong
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

4.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

5.  Finger nails as a reservoir for Candida albicans in recurrence of vaginal candidosis.

Authors:  V C Riley; F C Odds; P E Fisk; C E Webster
Journal:  Genitourin Med       Date:  1986-10

6.  Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis.

Authors:  J D Milne; D W Warnock
Journal:  Br J Vener Dis       Date:  1979-10

7.  Intermittent local prophylaxis against recurrent vaginal candidosis.

Authors:  T E Bushell; E G Evans; J D Meaden; J D Milne; D W Warnock
Journal:  Genitourin Med       Date:  1988-10

8.  The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis.

Authors:  I W Fong
Journal:  Genitourin Med       Date:  1994-04

9.  The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis.

Authors:  I W Fong
Journal:  Genitourin Med       Date:  1992-12

10.  Comparison of miconazole-coated tampons with clotrimazole vaginal tablets in the treatment of vaginal candidosis.

Authors:  M J Balsdon
Journal:  Br J Vener Dis       Date:  1981-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.